Format

Send to

Choose Destination
J Rheumatol. 2012 May;39(5):949-53. doi: 10.3899/jrheum.111134. Epub 2012 Apr 1.

Treating rheumatoid arthritis to target: a Canadian physician survey.

Author information

1
Université de Montréal, Montréal, Québec, Canada. bharaoui@videotron.ca

Abstract

OBJECTIVE:

To assess agreement and application of Treat to Target (T2T) recommendations in Canadian practice.

METHODS:

A survey of Canadian rheumatologists was conducted on the recommendations of T2T, an international initiative toward reaching specific therapeutic goals in rheumatoid arthritis. Agreement with each recommendation was measured on a 10-point Likert scale (1 = fully disagree, 10 = fully agree). A 4-point Likert scale (never, not very often, very often, always) assessed application of each recommendation in current practice. Responders who answered "never" or "not very often" were asked whether they were willing to change their practice according to the particular recommendation.

RESULTS:

Seventy-eight rheumatologists responded (24% of the 330 who were contacted). The average agreement scores ranged from 6.92 for recommendation #5 (the frequency of measures of disease activity) to 9.10 for recommendation #10 (the patient needs to be involved in the decision-making process). A majority of participants indicated that they apply the T2T recommendations in their practice. Recommendations dealing with frequency of visits and the use of composite measures received the highest number of "never" or "not very often" responses. Busy practices and lack of confidence in composite outcome measures were the main reasons for objections to certain components of the recommendations.

CONCLUSION:

Although a majority of Canadian rheumatologists agreed with and supported the T2T recommendations, there was resistance toward specific aspects of these recommendations. Efforts are needed to better understand the reasons behind identified disagreements. Action plans to encourage the application of T2T recommendations in Canada are in development.

PMID:
22467920
DOI:
10.3899/jrheum.111134
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center